Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B. Larsen CP, et al. Among authors: charpentier b. Transplantation. 2010 Dec 27;90(12):1528-35. doi: 10.1097/TP.0b013e3181ff87cd. Transplantation. 2010. PMID: 21076381
An integrated safety profile analysis of belatacept in kidney transplant recipients.
Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP. Grinyó J, et al. Among authors: charpentier b. Transplantation. 2010 Dec 27;90(12):1521-7. doi: 10.1097/TP.0b013e3182007b95. Transplantation. 2010. PMID: 21088650
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. Vincenti F, et al. Among authors: charpentier b. Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x. Am J Transplant. 2010. PMID: 20415897 Free article. Clinical Trial.
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Vincenti F, et al. Among authors: charpentier b. Am J Transplant. 2012 Jan;12(1):210-7. doi: 10.1111/j.1600-6143.2011.03785.x. Epub 2011 Oct 12. Am J Transplant. 2012. PMID: 21992533 Free article. Clinical Trial.
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, Vanrenterghem Y, Berthoux F, Bourbigot B, Delahousse M, Chalopin JM, Cassuto E, Lefrançois N. Glotz D, et al. Among authors: charpentier b. Transplantation. 2010 Jun 27;89(12):1511-7. doi: 10.1097/TP.0b013e3181db09e4. Transplantation. 2010. PMID: 20386144 Clinical Trial.
Five-year safety and efficacy of belatacept in renal transplantation.
Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, Klempnauer J, Lang P, Larsen CP, Mühlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B. Vincenti F, et al. Among authors: charpentier b. J Am Soc Nephrol. 2010 Sep;21(9):1587-96. doi: 10.1681/ASN.2009111109. Epub 2010 Jul 15. J Am Soc Nephrol. 2010. PMID: 20634298 Free PMC article. Clinical Trial.
Belatacept utilization recommendations: an expert position.
Grinyó JM, Budde K, Citterio F, Charpentier B. Grinyó JM, et al. Among authors: charpentier b. Expert Opin Drug Saf. 2013 Jan;12(1):111-22. doi: 10.1517/14740338.2013.748747. Epub 2012 Dec 4. Expert Opin Drug Saf. 2013. PMID: 23206310 Review.
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattström C, Charpentier B. Groth CG, et al. Among authors: charpentier b. Transplantation. 1999 Apr 15;67(7):1036-42. doi: 10.1097/00007890-199904150-00017. Transplantation. 1999. PMID: 10221490 Clinical Trial.
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, Matas A, Zhang R, Mühlbacher F, Pupim L, Florman S. Charpentier B, et al. Am J Transplant. 2013 Nov;13(11):2884-91. doi: 10.1111/ajt.12459. Epub 2013 Sep 18. Am J Transplant. 2013. PMID: 24103072 Free article. Clinical Trial.
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients.
Vanrenterghem Y, van Hooff JP, Klinger M, Wlodarczyk Z, Squifflet JP, Mourad G, Neuhaus P, Jurewicz A, Rostaing L, Charpentier B, Paczek L, Kreis H, Chang R, Paul LC, Grinyó JM, Short C. Vanrenterghem Y, et al. Among authors: charpentier b. Transplantation. 2004 Jul 15;78(1):9-14. doi: 10.1097/01.tp.0000132562.54089.62. Transplantation. 2004. PMID: 15257032 Clinical Trial.
467 results